Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07660731 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

A Phase 1 study, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
139
Enrollment target

NCT07660731: Recruiting Phase 1 study, sponsored by Pfizer.

NCT07660731 is a Phase 1 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 139 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (132% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07660731, a Phase 1 study, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
139 participants
Enrollment target

Study Summary

The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people. For Parts A, B, C, D and F, the study is seeking participants who: * Are healthy (do not have disease) males or females who can no longer have children, * Are 18 to 65 years old, * Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a body weight of more than 50 kilograms (110 pounds). Body mass index is a way to measure body fat by using a person's height and weight For Part A (optional group or cohort 3: Japanese participants only): * A body weight of more than 45 kilograms (100 pounds). * Have 4 biological Japanese grandparents who were born in Japan. For Part E only: * Adults with a documented history of asthma (confirmed by a doctor) for at least 12 months before entering the study. * Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). The study has six parts: Part A, Part B, Part C, Part D, Part E and Part F. The study medicine will be taken as a suspension or tablet by mouth 1 time a day (except in Parts B and E where it will be taken 1 time a day for 14 days) at the study clinic. The study will help understand: * how the body processes the study medicine in healthy participants (Parts A and B), * how much of the study medicine gets into the bloodstream and if food affects the amount of study medicine in the blood in healthy participants (Part C), * how the study medicine is broken down and leaves the body in healthy participants (Optional Part D), * how the study medicine is processed in adults with mild-to-moderate asthma (Optional Part E), * if taking the study medicine together with another medicine affects how each medicine is processed by the body in healthy participants (Optional Part F). Partic

Primary Outcome

Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional)

Interventions

  • DRUG Placebo
  • DRUG Midazolam
  • DRUG PF-08103402

Trial Details

FieldValue
Enrollment Target 139 participants
Start Date 2026-06-17
Est. Completion 2027-06-18
Phase Phase 1
Pfizer

1,845 total trials

What NCT07660731 shows while recruiting

NCT07660731 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (132% higher).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT07660731 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07660731 about?

NCT07660731 is a clinical study titled "A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma". The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people. For Parts A, B, C, D and F, the study is seeki...

What is the current status of trial NCT07660731?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 139 participants. The study started on 2026-06-17. Estimated completion is 2027-06-18.

What interventions are being tested in trial NCT07660731?

The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), PF-08103402 (DRUG).

Who is sponsoring clinical trial NCT07660731?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07660731's enrollment target sits among peer trials

139 418th of 2000 higher than 1,583 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05645380 · 139 participants · Phase 2

    Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

  • NCT06239272 · 139 participants · Phase 1

    NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • NCT06252220 · 139 participants · Phase 1

    First in Human Study in Subjects With Obesity, But Otherwise Healthy

  • NCT06537128 · 139 participants · NA

    Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07660731, the US trial registry maintained by the National Library of Medicine. NCT07660731 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.